"Early signs of trouble were appearing by the mid-1990s, when researchers began to document systematic positive bias in clinical trials funded by the pharmaceutical industry. Initially these biases seemed easy to address, and in some ways they offered psychological comfort. The problem, after all, was not with science, but with the poison of the profit motive. It could be countered with strict requirements to disclose conflicts of interest and to report all clinical trials."